On August 30, 2018 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO)
Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor
engineered T cell (CAR T) technology and gene therapies for rare diseases, reported that Manuel Litchman, M.D.,President and Chief Executive Officer, will participate in two investor conferences in September (Press release, Mustang Bio, AUG 30, 2018, View Source [SID1234529163]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
• B. Riley FBR Annual Healthcare Conference panel presentation entitled, "A Beginner’s Guide to T-Cell Cancer
Therapy" on Tuesday, September 4, 2018, at 1:55 p.m. EDT at the New York Marriott East Side in New York City
• 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC,
company presentation on Thursday, September 6, 2018, at 3:25 p.m. EDT at the St. Regis New York in New York
City